within Pharmacolibrary.Drugs.ATC.G;

model G02CX05
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 2.9833333333333335e-05,
    adminDuration  = 600,
    adminMass      = 1.75 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0253,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G02CX05</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Bremelanotide is a melanocortin receptor agonist used for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It is administered subcutaneously and is currently approved for this indication in the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy premenopausal women after a single subcutaneous dose.</p><h4>References</h4><ol><li><p>Mayer, D, &amp; Lynch, SE (2020). Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder. <i>The Annals of pharmacotherapy</i> 54(7) 684–690. DOI:<a href=\"https://doi.org/10.1177/1060028019899152\">10.1177/1060028019899152</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31893927/\">https://pubmed.ncbi.nlm.nih.gov/31893927</a></p></li><li><p>Sauter, M, Uhl, P, Burhenne, J, &amp; Haefeli, WE (2020). Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics. <i>Journal of pharmaceutical and biomedical analysis</i> 186 113276–None. DOI:<a href=\"https://doi.org/10.1016/j.jpba.2020.113276\">10.1016/j.jpba.2020.113276</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32353679/\">https://pubmed.ncbi.nlm.nih.gov/32353679</a></p></li><li><p>White, WB, Myers, MG, Jordan, R, &amp; Lucas, J (2017). Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide. <i>Journal of hypertension</i> 35(4) 761–768. DOI:<a href=\"https://doi.org/10.1097/HJH.0000000000001221\">10.1097/HJH.0000000000001221</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27977473/\">https://pubmed.ncbi.nlm.nih.gov/27977473</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G02CX05;
